Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)Xx_NEWLINE_xXTransaminases (serum glutamic pyruvic transaminase [SGPT] or alanine aminotransferase [ALT], and serum glutamic oxaloacetic transaminase [SGOT] or aspartate aminotransferase [AST]) less than 2.5 (two and a half) times the upper limits of institutional normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULN = 150 U/L; for the purpose of this study, the ULN for SGOT is 50 U/LXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x the institutional ULNXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase) [AST]); =< 150 U/L; for the purpose of this study, the ULN for SGOT is 50 U/LXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 1.5 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x upper limit of normal (ULN), must be obtained within 8 weeks prior to screening for protocol therapyXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 X institutional upper limit of normal (ULN) (=< 5 X if liver function test [LFT] elevations due to known liver metastases) must be obtained =< 7 days prior to protocol registrationXx_NEWLINE_xXWithin 2 weeks prior to registration: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 3 x normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULN (CTCAE v 3.0 grade 0-1)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULN obtained =< 21 days prior to registrationXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) less than or equal to 3.0 x ULN (CTCAE grade 1)Xx_NEWLINE_xXPatients with solid tumors: serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L)Xx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x upper limit of normal (ULN) if no liver metastasis; =< 5 x upper ULN if liver metastasis presentXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x ULN even in patients with documented hepatic involvement with lymphomaXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x ULN; AST and/or ALT may be up to 5 X ULN if thought to be secondary to leukemiaXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST] < 92.5 units/L)Xx_NEWLINE_xXAspartate aminotransferase (AST / serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT / serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN (=< 5 x if liver metastases are present) (for treatment phase)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 3 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXMeasured within 28 days prior to registration: aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normal or =< 5 × ULN if patient has liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXHepatic: Total or direct bilirubin ?2 × upper limit of normal (ULN); aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ?2.5 × ULN.Xx_NEWLINE_xXSubject has adequate vital organ function, as per protocol-defined laboratory values for Absolute Neutrophil count (ANC), platelets, hemoglobin, Prothrombin Time (PT) or International Normalized Ratio (INR), Partial Thromboplastin Time (PTT), measured or calculated creatinine clearance, serum total bilirubin, Aspartate aminotransferase (AST)/ Serum Glutamic Oxaloacetic Transaminase (SGOT), and Alanine aminotransferase (ALT)/ Serum Glutamic Pyruvic Transaminase (SGPT).Xx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3.0 x ULN (for the purpose of this study, the ULN for SGPT is 45 U/L)Xx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) =< 2.0 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases (only in the phase II portion)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN); =< 5.0 x institutional ULN for patients with documented liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) ? 2.5X institutional upper limit of normal within 14 days of registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) / (serum glutamic pyruvic transaminase [SGPT]) ? 2.5X institutional upper limit of normal within 14 days of registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases, performed within 14 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SPGT) =< 2.5 x institution's upper limit of normalXx_NEWLINE_xXCOHORT 1: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 X ULN within 14 days of treatment initiationXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) =< 2.5 x ULN, within 14 days of registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal, or =< 5 x institutional upper limit of normal in the setting of liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3.0 x institutional upper limit of normalXx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 × ULN or ? 5 × ULN for patients with liver metastasesXx_NEWLINE_xXAspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ? 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SPGT]) =< 3 X institutional ULNXx_NEWLINE_xXPatient must have adequate organ function as defined below:\r\n* Total bilirubin within normal institutional limits\r\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normal\r\n* Creatinine clearance >= 10 mL/min/1.73 m^2Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 3 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) >= 3 times the upper limit of normal (if related to liver metastases >= 5 times the upper limit of normal)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x IULN, =< 5 x IULN for patients with liver metastasesXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5 x upper limit normal (ULN) for ageXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) /alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULN, OR AST(SGOT)/ALT(SGPT) =< 5 x institutional ULN if liver metastases are presentXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 x institutional ULN ? 5.0 x institutional ULN for patients with documented liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normal or < 5 times the ULN in the presence of liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) =< 5 times institutional upper limitXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) > 3 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normal or < 5 times the ULN in the presence of liver metastasesXx_NEWLINE_xXAlkaline phosphatase (hepatic) or serum glutamic-oxaloacetic transaminase (SGOT) > 3 times the upper normal limitXx_NEWLINE_xXObtained within 14 days prior to registration: Serum glutamic oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) =< 135 U/L; for the purpose of this study, the ULN for ALT is 45 U/LXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) aspartate aminotransferase [AST] =< 3 x ULN = 150 U/L; for the purpose of this study, the ULN for SGOT is 50 U/LXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) < 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3.0 times institutional upper limit of normal for age and documented within 14 days prior to registration and within 14 days prior to the start of treatmentXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional upper limit of normal (=< 5 x ULN if known liver metastases)Xx_NEWLINE_xXAdequate liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), ?3 × the upper limit of normal (ULN) (AST/ALT ?5 × ULN if transaminase elevation is related to MF), direct bilirubin ?4× ULN, and creatinine ?2.5 mg/dLXx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN); serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 5 is permissible if due to diseaseXx_NEWLINE_xXWithin 28 days of study registration: Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x upper limit of normal (ULN) for ageXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 1.2 x institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) ? 2 x institutional ULN within 28 days prior to registrationXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ? 2 x institutional ULN within 28 days prior to registrationXx_NEWLINE_xXAspartate Transaminase (AST), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alanine Transaminase (ALT), Serum Glutamic-Pyruvic Transamine (SGPT) ? 3 × ULN (if liver metastases are present, then ? 5 × ULN is allowed)Xx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXTransaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT) =< 2.5 x institutional ULN (=< 5 x institutional ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]): 5-35 U/LXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.0 x upper normal limit (UNL)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]): =< 5 X the upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXPerformed within 10 business days of treatment initiation with the exception of beta- HCG (72 hours), if applicable: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases.Xx_NEWLINE_xXWithin 14 days of randomization: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) (serum glutamic oxaloacetic transaminase [SGOT]/serum glutamic pyruvic transaminase [SGPT]) =< 3 times institutional normal limits.Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normal (=< 5 x ULN in the presence of liver metastases), =< 5 days prior to C1D1Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine transaminase [ALT] (serum glutamic pyruvic transaminase [SPGT]) =< 5 x institutional upper limit of normalXx_NEWLINE_xXSignificant hepatic dysfunction (serum glutamic-oxaloacetic transaminase [SGOT] > 5x upper limit of normal; bilirubin > 3.0 mg/dL)Xx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) =< 2.5 times the institutional upper limits of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =< 3 x ULN, obtained =< 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases, performed within 28 days of treatment initiationXx_NEWLINE_xXWithin 3 days prior to enrollment: alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) and aspartate aminotransferase (AST)/Serum Glutamic Oxaloacetic Transaminase (SGOT) must be < 5 x the upper limit of the normal range.Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases, should be performed within 10 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =< 3 x IULN (or =< 5 x IULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ? 10 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) less than 5 X ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULN and serum glutamic pyruvic transaminase (SGPT) =< 2.5x ULNXx_NEWLINE_xXWithin 28 days prior to treatment start: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 3 x institutional upper limit of normal.Xx_NEWLINE_xXTransaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present).Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases, performed within 10 days of treatmentXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 X ULN OR ? 5 X ULN for subjects with liver metastases within 21 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases within 21 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases (performed within 10 days of treatment initiation)Xx_NEWLINE_xXWithin 28 days prior to administration of study treatment: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 3 times institutional ULN unless liver metastases are present in which case they must be < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =<1.5 x institutional upper limit of normal or =< 2.5 x upper limit of normal (ULN) for patients with liver metastases; this will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 x upper limit of normal range (ULN) obtained ? 14 days prior to randomizationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) >= 2 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (aspartate aminotransaminase [AST], serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (alanine aminotransaminase [ALT], serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) < 3 × ULNXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT) and alkaline phosphatase <3 times the ULN) unless due to organ involvementXx_NEWLINE_xXAspartate transaminase (AST) / alanine transaminase (ALT) (serum glutamic oxaloacetic transaminase [SGOT]/serum glutamic-pyruvic transaminase ([GPT]) =< 2 times institutional normal limitsXx_NEWLINE_xXSerum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 times institutional upper limit of normal for ageXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 times institutional upper limit of normal for ageXx_NEWLINE_xXAspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) =< 2.5 x institutional ULN or =< 5 x institutional ULN in the presence of liver metastases.Xx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) less than or equal to 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 5 X ULN for subjects, performed within 10 days of treatment initiationXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) =< 1.5 times upper limit of normal (prior to biopsy)Xx_NEWLINE_xXWithin 7 days prior to administration of study treatment: Aspartate aminotransferase (serum glutamine oxaloacetic transaminase) and alanine aminotransferase (serum glutamic pyruvic transaminase) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be =< 5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULNXx_NEWLINE_xXObtained with 21 days of registration: aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAlanine transaminase or aspartate transaminase ? 5 times the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases, performed within 10 days of treatment initiationXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x ULN for ageXx_NEWLINE_xXSerum aspartate transaminase or alanine transaminase =< 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminas [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 3.0 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal within 30 days of registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]): =< 5 x the ULNXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ? 2.5 times upper limit of normal (ULN) or ? 5 times ULN in cases of liver metastasesXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x ULN, or =< 5 x ULN in patients with documented liver metastases within 14 days of cycle 1 day 1Xx_NEWLINE_xXAspartate transaminase (AST, serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT, serum glutamic pyruvic transaminase [SGPT]) =< 3.0 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal 14 days or fewer from registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases, performed within 10 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) >= 2 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAdequate liver function: serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) and serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT) ? 2 × ULN and serum bilirubin ? 1.5 × ULN unless Gilbert's syndrome has previously been confirmed for the subjectXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 3 x upper limit of normal, within 28 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN within 14 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal, measured within 28 days prior to administration of study treatment\r\n* Note: patients with elevations in bilirubin, AST, or ALT should be thoroughly evaluated for the etiology of this abnormality prior to entry and patients with evidence of viral infection should be excludedXx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 3 times upper limit of normal (ULN) within 30 days of enrollment to studyXx_NEWLINE_xXPerformed within 14 days (+ 3 working days) prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) and bilirubin < 2 times upper limit of normal (ULN).Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =< 5 x ULN within 28 days prior to study registrationXx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X ULN obtained =< 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT/serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXTransaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) =< 2.5 x normal prior to biopsyXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) =< 2.5 X ULN or =< 5 X ULN for subjects with liver metastases (within 10-15 days of treatment initiation)Xx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) less than or equal to 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases, during screening and on cycle 1, day 1Xx_NEWLINE_xXAlanine aminotransferase (ALT/serum glutamic pyruvic transaminase [SGPT]) and aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 1.5 X ULN (performed within 10 days of treatment initiation)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 3 x institutional upper limit of normalXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L; for the purpose of this study, the ULN for SGPT is 45 U/LXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normalXx_NEWLINE_xXWithin 10 days of treatment initiation: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.0 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]): =< 2.5 X ULN OR =< 5 X ULN for participants with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULNXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x laboratory upper limit of normal (ULN)Xx_NEWLINE_xXCompleted within 60 days of surgery: Aspartate aminotransferase AST (serum glutamic oxaloacetic transaminase SGOT) and alanine aminotransferase ALT (serum glutamic pyruvic transaminase SGPT) < 3 times the upper limit of the institutional normalXx_NEWLINE_xXCompleted within 10 days of SBRT treatment initiation: Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) less than 1.5 times the upper limits of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x upper limit of normal or =< 5 x ULN if due to lymphoma infiltrationXx_NEWLINE_xXWithin 14 days prior to registration: Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)/ alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SPGT) =< 2.5 X institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 × institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 3.0 x institutional upper limit of normal (IULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 5 x upper limit of normal (ULN) (CTCAE grade 2 baseline)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 3 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x upper limit of normal (=< 5 x ULN if liver metastases present)Xx_NEWLINE_xXHepatic: transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) > 5 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXObtained =< 14 days prior to registration: Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 X institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 x upper limit of normal (ULN), except if there is known hepatic metastasis, wherein transaminases may be =< 5 x institutional ULNXx_NEWLINE_xXPerformed within 14 days (+3 working days) of treatment initiation: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) > 2 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) less than or equal to 3 X the upper limit of normal (ULN) for the reference lab unless due to leukemia or congenital hemolytic disorder or bilirubin excretion disorder; patients with hepatic dysfunction (SGOT/SGPT up to less than or equal to 5 X ULN) due to organ infiltration by disease may be eligible after discussion with the principal investigator and appropriate dose adjustments will be consideredXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXTransaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x IULN, unless there are liver metastases in which case AST and ALT =< 5.0 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) ? 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ? 5 x ULNXx_NEWLINE_xXSerum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 3 x the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST [serum glutamic oxaloacetic transaminase (SGOT)] and alanine aminotransferase (ALT [serum glutamic pyruvate transaminase (SGPT)]) =< 2.5 X ULNXx_NEWLINE_xXPerformed within 28 days prior to study registration up to the first dose of study drug: Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =< 2.5 X ULN or =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN in cases of liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 5 x institutional upper limit of normalXx_NEWLINE_xXAspartate transaminase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine transaminase (ALT)/serum glutamic-pyruvate transaminase (SGPT) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present; Gilbert’s disease is allowedXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) levels =< 3 x the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULNXx_NEWLINE_xXAminotransferase (aspartate aminotransferase [AST]) serum glutamic oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (patients with liver involvement will be allowed =< 5.0 x institutional upper normal limit)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 4 times institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) >= 2 x institutional upper limit of normalXx_NEWLINE_xXWithin 30 days of first vaccination: Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 2 times upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal < 5 x upper limit of normal (ULN) if patient has liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL) obtained =< 2 weeks prior to enrollmentXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) > 5 x upper limit of normalXx_NEWLINE_xXAlkaline phosphatase (hepatic) or serum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper normal limitXx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN or SGOT (AST) and SGPT (ALT) =< 5 x ULN is acceptable if liver has tumor involvementXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN; =< 5 x ULN if liver metastasisXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) =< 2.5 × upper limit of normal of institution's normal range (ULN) (=< 5.0 × ULN with liver metastasis)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULN, within 14 days prior to study entryXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 1.5 x ULN for ageXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 3 x ULN or =< 5 x ULN in patients with known liver metastasisXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 2 times upper limit of normal (ULN) (performed within 14 days prior to registration)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 3 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 times institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]):\r\n* If no known liver metastases: AST/SGOT and ALT/SGPT both < 2 x ULN\r\n* If known liver metastases, then: AST/SGOT and ALT/SGPT both < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) =< 3.0 x local institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) =< 3.0 x local institutional ULNXx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXSerum transaminase (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT], alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]) activity =< 2.5 x ULNXx_NEWLINE_xXSevere hepatic disease (direct bilirubin > 3 mg/dl or serum glutamic oxaloacetic transaminase [SGOT] > 500)Xx_NEWLINE_xXAny pre-treatment laboratory findings within 15 days of treatment demonstrating liver dysfunction: • AST (Serum Glutamic-Oxalacetic Transaminase - SGOT) or ALT (Serum Glutamic-Pyruvic Transaminase - SGPT) > 5 times Upper Normal Limit (UNL) • Serum bilirubin > 2.0 mg/dl (unless segmental infusion is planned)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 5 x upper normal limits (UNL)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 2.5 X ULN, should be performed within 10 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x upper limit of normal (ULN) (=< 5.0 x ULN in patients with known liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2 X institutional upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) < 2 x upper limit of normal (ULN) performed within 60 days of enrollmentXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be =< 5 x ULN within 28 days prior to administration of study treatment.Xx_NEWLINE_xXWithin 28 days prior to administration of study treatment: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ? 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ? 5x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 X ULN OR ? 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) within institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) < 2.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases, within 14 days prior to first dose of pembrolizumabXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) ? 1.5 X institutional upper limit of normal (ULN) within 14 days prior to registrationXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ? 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 X ULN within 7 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN, performed within 28 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) ? 3 x upper normal limit (UNL), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ? 3 x UNL ? 2 weeksXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULNXx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) less than or equal to 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be =< 5 x ULN.Xx_NEWLINE_xXAminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 3 x upper limit of normal.Xx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 108 u/LXx_NEWLINE_xXAspartate aminotransferase ([AST]; serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase ([ALT]; serum glutamic pyruvate transaminase [SGPT]) =< 2.5 times ULN, (if liver metastases are present, then =< 5 times ULN is allowed)Xx_NEWLINE_xXAspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x ULN, obtained within 14 days prior to registration for protocol therapyXx_NEWLINE_xXAlanine aminotransferase (ALT, serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN, obtained within 14 days prior to registration for protocol therapyXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 x upper limit of institutional normalXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x ULN in the absence of hepatic metastasis; SGPT (ALT) =< 3 x ULN or SGOT (AST) =< 5 x ULN in the presences of hepatic metastasisXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXDOSE ESCALATION COHORT: Aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ? 2.5 X institutional upper limit of normal (ULN)Xx_NEWLINE_xXDOSE ESCALATION COHORT: Alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SPGT]) ? 2.5 X ULNXx_NEWLINE_xXMeasured within 28 days prior to administration of study treatment: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 3 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULN; EXCEPTION: subjects with documented liver metastases: AST and/or ALT =< 5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) < 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x ULNXx_NEWLINE_xXObtained =< 7 days prior to registration: Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN (=< 5 x ULN for participants with liver metastases), specimens must be collected within 10 days prior to the start of study treatmentXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine transaminase [ALT]) < 2 x ULN for ageXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 3 times the institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase ALT (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 125 U/L; for the purpose of this study, the ULN for SGOT is 50 U/LXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 4 times the institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) & alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 5 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvate transaminase (SGPT) =< four times the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) less than or equal to 3 x ULN (CTEP CTCAE version 4.0, grade 1)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 3 X laboratory normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal in the absence of liver metastasis; SGOT/AST < 5.0 times ULN in the presence of liver metastasisXx_NEWLINE_xXAbsolute neutrophil count ? 1500 cells/mm3. 9. Platelets ? 100,000 cells/mm3. 10. Hemoglobin ? 9 g/dL. 11. Aspartate transaminase/serum glutamic oxaloacetic transaminase, alanine transaminase/serum glutamic pyruvic transaminase ? 2.5 × upper limit of normal range or ? 5.0 × upper limit of normal range if liver metastases.Xx_NEWLINE_xXIf no known liver metastases: aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) < 2 x ULN; if known liver metastases, then: AST/SGOT < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULN or =< 5 x institutional ULN for participants with documented liver metastasesXx_NEWLINE_xXSerum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (SGOT/AST) or alanine aminotransferase (SGPT/ALT) > 2.5 × upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) greater than 3.0 x ULN (CTCAE v4.0 grade 1) (if known hepatic metastases SGOT may be =< 5 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT) ?2.5x ULNXx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 x institution's upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases, performed within 10 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x upper limit of normalXx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X institutional ULNXx_NEWLINE_xXWithin 14 days prior to registration: aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) =< 2.5 X institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 X ULN for participants with liver metastases (within 14 days of treatment initiation)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3.0 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) less than or equal to 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST), Serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT), serum glutamic pyruvic transaminase (SGPT) ? 2.5 x upper limit of normal range (ULN), or ? 5 x ULN range if liver metastasis presentXx_NEWLINE_xXSerum aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x upper limit of normal (ULN)Xx_NEWLINE_xXWithin 4 weeks of administration of study therapy: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN or =< 5 x ULN for patients with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 x ULN OR =< 5 x ULN for subjects with lymphoma in the liver, performed within 28 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 x institutional upper limit of normal (IULN) except when in the opinion of treating physician is due to direct involvement of leukemia (e.g. hepatic infiltration or biliary obstruction due to leukemia) or Gilbert's diseaseXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 1.5 times upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) < 3 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are presentXx_NEWLINE_xXAspartate aminotransaminase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase levels (SGPT) =< 2.5 X ULN (unless the patient has liver metastases)Xx_NEWLINE_xXWithin 14 days of registration: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2 x upper limits of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and/or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 × the upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST), or serum glutamic pyruvic transaminase (SGPT)/ alanine aminotransferase (ALT) > 3.0 × ULNXx_NEWLINE_xXTransaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) ? 1.5 X ULN (< 2.5 X ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) Serum glutamic-oxaloacetric transaminase (SGOT), Alanine aminotransferase ALT (Serum glutamic pyruvate transaminase SGPT) ? 2.5 × upper limit of normal range (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x UNLXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be =< 5x ULN.Xx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times the upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 2 x upper limit of normal (ULN) (or < 5 x ULN if liver is involved)Xx_NEWLINE_xXObtained =< 7 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal (ULN) (or =< 5 x ULN if in the investigator's opinion the elevation is due to extramedullary hematopoiesis)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) or aspartate aminotransferase (AST) =< 2.5 times the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) < 3 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are presentXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.0 x institutional upper limit of normal (unless known hepatic involvement then < 3.5 x institutional upper limit)Xx_NEWLINE_xXObtained within 14 days prior to registration: Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2 times upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULN, CTCAE grade 1Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x institutional upper limit normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) < 2 X upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 1.5 x ULN; AST and/or ALT may be up to 5 X ULN if with known liver metsXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 2 times upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransaminase (AST) (serum glutamic oxalic transaminase [SGOT]) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional ULN (concomitant elevations in bilirubin and AST/ALT above 1.0 X ULN are not permitted)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) levels =< 2 x ULNXx_NEWLINE_xXSerum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN or =< 5 x upper limit of normal (ULN) if hepatic metastases are presentXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT)(aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal OR =< 5 x upper limit of normal if liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN or =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic-oxalacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <2.5 x ULN, or, in the presence of documented liver metastases, ?5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 x ULNXx_NEWLINE_xXAspartate transferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN (serum glutamic oxaloacetic transaminase [SGOT])Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times the upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 1.5 x normalXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) (serum glutamic oxaloacetic transaminase [SGOT]/serum glutamic pyruvic transaminase [SGPT]) < 2 times institutional normal limits, or up to 5 times institutional normal limits if the patient has liver metastasesXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.0 times normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT, serum glutamic-pyruvic transaminase [SGPT]) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXSerum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 2.5 X upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase - serum glutamic oxaloacetic transaminase (AST(SGOT)) and alanine aminotransferase - serum glutamic pyruvic transaminase (ALT(SGPT)) less than or equal to 2.5 X upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x IUNLXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 3 times normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 2 upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 3 x institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x upper limit of normalXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x laboratory upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]), alanine transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) ? 2.5 × upper limit of normal range (ULN) or ? 5.0 × ULN if liver metastases.Xx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) < 3 X institutional upper limit of normalXx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X institutional upper limit of normal or =< 5 X institutional upper limit of normal for patients with known liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) & Alanine Aminotransferase (ALT)/Serum Glutamic Pyruvic (SGPT) ?3.0 x Upper Limit of Norma (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels =< 2 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 1.5 times upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferse [AST]) =< 3 x ULN, unless evidence of direct liver involvement by lymphoma, then =< 5 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT)/ aspartate aminotransferase (AST) or Transaminase, serum glutamic pyruvic (SGPT)/ alanine aminotransferase (ALT) > 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 3.0 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 x upper limit of normal (ULN), except if there is known hepatic metastasis, wherein transaminases may be =< 5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase AST (serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase ALT > 2 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 2.5 X upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) < 3 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 3 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/aspartate aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT >= 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransaminase [ALT]) =< 225 units per liter (U/L); for the purpose of this study, the ULN for SGPT is 45 U/LXx_NEWLINE_xXSerum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x laboratory upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper normal limitXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) > 150 IU or > 3 x upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) < 5.0 x IULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) < 3 times upper limits of normal =< 120 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ? 2.5 × institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 135 U/L; for the purpose of this study, the upper limit of normal (ULN) for ALT is 45 U/LXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) < 3 x normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 1.5 times upper limit of normalXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) =< 1.5 x upper limit of normal (ULN) obtained =< 180 days prior to registrationXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULNXx_NEWLINE_xXSerum glutamic-pyruvic transaminase (SGPT) =< 2.5 x ULNXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULNXx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) < 2 x upper limit of normal for ageXx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum aspartate transaminase (AST) and alanine transaminase (ALT) =< 4.0 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 3 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) =< 2 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 1.5 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) =< 2 times upper limit of normal (ULN) within 90 days of enrollmentXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic pyruvic transaminase (SGPT) =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT), and gamma-glutamyltransferase (GGT) ?2.5 xupper limit of normal (ULN) (AST/ALT/GGT ?5 xULN if documented hepatic involvement with lymphoma)Xx_NEWLINE_xXAST (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X upper normal level (UNL)Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 × institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x institutional ULN obtained =< 45 days prior to randomizationXx_NEWLINE_xXSerum AST/SGOT (Aspartate transaminase / Serum glutamic oxaloacetic transaminase) or ALT/SGPT (Alanine aminotransaminase / Serum glutamic pyruvate transaminase) > 2.5 x ULN (upper limit of normal)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 ULN, obtained within 14 days prior to treatment startXx_NEWLINE_xXAsparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ? 2.5 x Upper Limit of Normal (ULN) or ? 5.0 X ULN if liver tumor is present.Xx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULN unless liver metastases are present, in which case it must be =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (=< 5 x upper limit of normal for patient with liver metastasis)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) < 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]), and serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) must be less than 4 x upper limit of normalXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) > 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) =< 2.5 x upper limits of normal if no liver metastases present; SGOT, SGPT =< 5 x upper limits of normal if liver metastases presentXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 X ULN OR =< 5 x ULN for subjects with liver metastases, performed within 10 days of treatment initiationXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 3 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) ? institutional upper limit of normalXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT) < 2 times upper limit of normal (ULN), performed within 28 days prior to registrationXx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGOT) > 150 IU or > 3 x upper limit of normalXx_NEWLINE_xXSerum glutamic-oxaloacetic transaminase (SGOT)(aspartate aminotransferase [AST]) or serum glutamic-pyruvic transaminase (SGPT)(alanine aminotransferase [ALT]) levels =< 2 x ULNXx_NEWLINE_xXAspartate transaminase (serum glutamic oxaloacetic transaminase)/alanine transaminase (serum glutamic pyruvic transaminase (AST[SGOT]/ALT[SGPT]) =< 2.5 x ULN (5 x ULN for patients with concurrent liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 1.5 X institutional upper limit of normal (or =< 3 X upper limit of normal [ULN] in the setting of liver metastases)Xx_NEWLINE_xX